The use and impact of bevacizumab (Avastin) for the treatment of metastatic colorectal cancer treatment in Australia

Access & Terms of Use
metadata only access
Copyright: University of New South Wales
Access to the data is subject to originating data custodian approval. Ethics committee approval and other access conditions apply.
This project was established to conduct a long-term evaluation of the way in which bevacizumab (Avastin) is used to treat metastatic colorectal cancer in the real world clinical setting. Bevacizumab became available under the Pharmaceutical Benefits Scheme (PBS) in July 2009. This study has access to the PBS history of all patients prescribed bevacizumab since its PBS-subsidy and has approval for annual data updates until 2016. Originating source(s): Medicare Australia [Pharmaceutical Benefits Scheme] [Patient/Medicare enrolment data]
Persistent link to this record
Link to External Data Repository
Electronic Location
Contact Information
Access type: Access by request. Contact the Information Officer for more information:
Research Data Creator(s)
Lead Chief Investigator
Other Contributor(s)
Corporate/Industry Contributor(s)
Adult Cancer Program, Lowy Cancer Research Centre
Publication Year
Resource Type
Drug treatments
Patterns of cancer care
UNSW Faculty
Related dataset(s)
Related publication(s)
Related grant(s)
Use of bevacizumab in Australia